市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | GH Research PLC | 看涨 | 看涨 |
AIStockmoo 评分
0.1
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.13 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 33.88% |
| 机构持股比例 | 68.90% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Highvista Strategies Llc | 30 Sep 2025 | 241,894 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 70.00 (HC Wainwright & Co., 376.19%) | 购买 |
| 中 | 40.00 (172.11%) | |
| 低 | 32.00 (Needham, 117.69%) | 购买 |
| 平均值 | 44.60 (203.40%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 15.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citizens | 06 Mar 2026 | 42.00 (185.71%) | 购买 | 15.93 |
| Needham | 06 Mar 2026 | 32.00 (117.69%) | 购买 | 15.93 |
| 06 Jan 2026 | 29.00 (97.28%) | 购买 | 14.12 | |
| HC Wainwright & Co. | 02 Mar 2026 | 70.00 (376.19%) | 购买 | 16.01 |
| RBC Capital | 23 Jan 2026 | 40.00 (172.11%) | 购买 | 16.73 |
| Canaccord Genuity | 06 Jan 2026 | 39.00 (165.31%) | 购买 | 14.12 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Jan 2026 | 公告 | GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 |
| 02 Jan 2026 | 公告 | GH Research to Announce IND Status for GH001 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合